Rare biomarker specimen market seen reaching $55.35 billion by 2030

By AI, Created 1:12 PM UTC, June 04, 2026, /AGP/ – The rare biomarkers specimen collection and stabilization market is projected to rise from $35.29 billion in 2025 to $38.94 billion in 2026, then climb to $55.35 billion by 2030. The growth outlook reflects rising demand for precision diagnostics, early disease detection, biomarker-based drug development and better sample preservation.

Why it matters: - Rare biomarker specimen collection and stabilization underpins advanced diagnostics and research by helping preserve low-abundance biological signals for accurate testing. - Growth in precision medicine, liquid biopsy and biomarker-driven drug development is increasing demand for reliable sample handling. - Better specimen integrity can improve diagnostic accuracy, especially in oncology and other disease areas that rely on rare biomarker detection.

What happened: - The rare biomarkers specimen collection and stabilization market is projected to grow from $35.29 billion in 2025 to $38.94 billion in 2026. - The market is forecast to reach $55.35 billion by 2030. - The report pegs 2025-2026 growth at a 10.3% CAGR and 2026-2030 growth at a 9.2% CAGR. - The Business Research Company published the market outlook on June 4, 2026. - The report includes a free sample and the full market report.

The details: - The market covers collection and preservation of biological samples containing rare or low-abundance molecules. - Those biomarkers can include proteins, nucleic acids, metabolites and other substances linked to biological processes, diseases or conditions. - The goal is accurate and reliable measurement for diagnostic, prognostic and therapeutic use. - Historical growth has been supported by molecular diagnostics research, oncology biomarker studies, broader plasma-based testing, more clinical trial activity and greater use of biobanking. - Future growth drivers include broader precision diagnostics adoption, rising early disease detection demand, expansion in genomic and transcriptomic testing, more biomarker-driven drug development and deeper use of artificial intelligence in biomarker analysis. - Key forecast-period trends include wider use of liquid biopsy collection techniques, more advanced stabilization reagents, higher demand for high-sensitivity biomarker preservation, growth in non-invasive diagnostics, and stronger focus on sample integrity and traceability. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - Other covered regions include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The market’s trajectory suggests biomarker workflows are moving from specialized research tools toward broader clinical use. - AI, liquid biopsy and non-invasive testing are converging on the same problem: making hard-to-detect biological signals easier to capture and trust. - Regional growth is likely to track healthcare investment, trial activity and adoption of precision medicine infrastructure.

What’s next: - The market is expected to keep expanding through 2030 as diagnostics and drug development shift toward more personalized, data-driven approaches. - The Business Research Company says its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, and updated graphics and tables. - The company also points readers to related reports on blood transfusion diagnostics, hematology diagnostic devices and immunochemistry diagnostic devices.

The bottom line: - Rare biomarker specimen collection and stabilization is becoming a core enabling market for precision diagnostics, and the next growth leg appears tied to non-invasive testing, AI-enabled analysis and better sample preservation.